RCS - Genflow Biosciences - Review of 2025

Genflow BiosciencesAnnouncement

08/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260108:nRSH0766Oa&default-theme=true

RNS Number : 0766O  Genflow Biosciences PLC  08 January 2026

08 January 2026

 

A Review of an Exciting 2025

 

2025 has been a year of focused scientific progress and continued advancement
of Genflow Bioscience's mission to extend healthy lifespan through our novel
longevity gene therapy platform. Across our portfolio, we have maintained
momentum in both animal health where progress in our canine study may provide
translational insights relevant to future human applications as well as
therapeutic development for dogs.

 

These advancements have been supported by a strengthened network of leading
academic collaborators and laboratories. Together, with continued backing from
international institutional investors and previously awarded government
grants, this ecosystem helped accelerate Genflow's scientific and clinical
development throughout 2025.

 

Program Highlights

 

We've made a number of notable strides across our programs this year,
including:

·      Dog Aging (GF-1004)

We made significant strides in our clinical trial for aging dogs with full
administration of our investigational SIRT6-based gene therapy now completed.
No adverse events were reported during the dosing phase of the study, with no
serious, moderate, or minor side effects observed. The study which began in
March 2025, is being conducted as a blinded clinical trial; an initial
efficacy readout is expected in Q1 2026, including blood analyses and muscle
biopsies to evaluate potential benefits related to sarcopenia, healthspan, and
lifespan-associated biomarkers.

 

Dogs enrolled in the trial will be monitored for 180 days, with a second
efficacy assessment planned at the six-month timepoint and results expected in
June-July 2026 to evaluate durability and longer-term effects.

 

·      MASH (GF-1002)

Our MASH program saw good progress in 2025. While GLP-1 therapies have
addressed early-stage MASH, patients with advanced fibrosis - roughly
one-third of the population - still face limited treatment options. In
response, we repositioned GF-1002 to target this high-need group, leveraging
its antifibrotic properties and potential to prevent progression to cirrhosis
and liver cancer. Additionally, we have generated new pre-clinical POC data on
the prevention of HCC.

 

We are now finalizing our IND package and evaluating mRNA/LNP delivery as an
alternative to AAV, an approach that could enable repeat dosing and lower
manufacturing costs. Encouraging data continue to support this next phase of
research and development.

·      Glaucoma

In 2025, we expanded into ophthalmology, where SIRT6-based gene therapy shows
promise in glaucoma, a leading cause of irreversible blindness. Current
treatments primarily manage intraocular pressure but do little to prevent
optic nerve degeneration. Our preclinical data suggest SIRT6 overexpression
may protect retinal ganglion cells and preserve optic nerve function, shifting
the focus from symptom control to true neuroprotection.

 

We are advancing discussions with a leading LNP partner to support delivery
innovation in this space and are securing a full-service CRO to manage
formulation through preclinical execution. With the global glaucoma market
approaching USD $12-14 billion by the early 2030s, this represents a
compelling long-term opportunity for us.

 

·      Additional Programs

We continued to advance our broader pipeline and are pleased with the steady
advancement of the sarcopenia program, fully consistent with our development
plans. In parallel, the ExoFastTrack initiative continues to move forward,
generating important data that will support and accelerate several of our
other development programs.

 

Looking Ahead to 2026

As we move into 2026, we do so with confidence, discipline, and a clear
strategic focus. The coming year will emphasize rationalization of our
pipeline, prioritizing programs with the strongest data, clearest paths to
value creation, and highest partner interest. Central to this strategy will be
the pursuit of early-stage licensing and collaboration agreements designed to
generate non-dilutive funding, validate our platform externally, and support
continued development without undue capital strain.

With multiple upcoming data readouts, an expanding partner network, and a
maturing intellectual property position, we believe Genflow is well positioned
to enter its next phase of growth. We remain committed to scientific
excellence, capital efficiency, and long-term value creation as we work to
translate our longevity platform into meaningful therapies.

Thank you for your continued support and confidence in Genflow.

 

Dr. Eric Leire

Founder & Chief Executive Officer

 

Contacts

 

 Genflow Biosciences  Harbor Access
 Dr Eric Leire, CEO   Jonathan Paterson, Investor Relations
 +32-477-495-881      +1 475 477 9401
                      Jonathan.Paterson@Harbor-access.com

 

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies to decelerate the aging process, with
the goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging global
population. Genflow's lead compound, GF-1002, works through the delivery of a
centenarian variant of the SIRT6 gene which has yielded promising preclinical
results. Genflow's 12-month proof-of-concept clinical trial evaluating their
SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other
programs, include a clinical trial that will explore the potential benefits of
GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis),
the most prevalent chronic liver disease for which there is no effective
treatments. Please visit www.genflowbio.com (http://www.genflowbio.com/)
and follow the Company on LinkedIn
(https://www.linkedin.com/company/genflow-biosciences/?viewAsMember=true)
 and X (https://x.com/genflowbio) .

 

DISCLAIMER

The contents of this announcement have been prepared by, and are the sole
responsibility of, the Company.

 

This announcement may contain forward-looking statements. The forward-looking
statements include, but are not limited to, statements regarding the Company's
or the Directors' expectations, hopes, beliefs, intentions or strategies
regarding the future. In addition, any statement that refers to projections,
forecasts or other characterisations of future events or circumstances,
including any underlying assumptions, is a forward-looking statement. The
words "anticipate", "believe", "continue", "could", "estimate", "expect",
"intend", "may", "might", "plan", "possible", "potential", "predict",
"project", "seek", "should", "would" and similar expressions, or in each case
their negatives, may identify forward-looking statements, but the absence of
these words does not mean that a statement is not forward-looking.

 

Forward-looking statements include all matters that are not historical facts.
Forward-looking statements are based on the current expectations and
assumptions regarding the Company, the business, the economy and other future
conditions. Because forward-looking statements relate to the future, by their
nature, they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict. Forward-looking statements are
not guarantees of future performance and the Company's actual financial
condition, actual results of operations and financial performance, and the
development of the industries in which it operates or will operate, may differ
materially from those made in or suggested by the forward-looking statements
contained in this announcement. In addition, even if the Company's financial
condition, results of operations and the development of the industries in
which it operates or will operate, are consistent with the forward-looking
statements contained in this announcement, those results or developments may
not be indicative of financial condition, results of operations or
developments in subsequent periods. Important factors that could cause actual
results to differ materially from those in the forward-looking statements
include regional, national or global, political, economic, social, business,
technological, competitive, market and regulatory conditions.

 

Any forward-looking statement contained in this announcement applies only as
of the date of this announcement and is expressly qualified in its entirety by
these cautionary statements. Factors or events that could cause the Company's
actual plans or results to differ may emerge from time to time, and it is not
possible for the Company to predict all of them. The Company expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained in this announcement to
reflect any change in its expectations or any change in events, conditions or
circumstances on which any forward-looking statement contained in this
announcement is based, unless required to do so by applicable law, the
Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and
Transparency Rules of the FCA or the UK Market Abuse Regulation.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASSFEEWEMSEEF



            Copyright 2019 Regulatory News Service, all rights reserved